BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing proprietary drug delivery technologies to develop and commercialize novel prescription, over-the-counter and supplement products that address large markets in dermatology and women’s health. The Company’s objective is to develop products that treat health or age-related conditions that are not presently being addressed or treated at all or are currently treated with drug therapies or drug delivery approaches that are sub-optimal. BioPharmX has developed a product portfolio using its drug delivery technologies, including delivery mechanisms for antibiotics, biologic materials, and molecular iodine.

The Company currently has one marketed product, a VI2OLET iodine dietary supplement, two clinical‑stage product candidates, BPX01 and BPX03 and one development‑stage product candidate, BPX02. VI2OLET is a molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches, and swelling. BPX03 is a prescription drug version of the molecular iodine tablet for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia. BPX01 is a hydrophilic, topical antibiotic gel for the treatment of acne vulgaris and BPX02 is an injectable product utilizing biologic materials for aesthetic dermatology applications.


Show more
TypePublic
HQMenlo Park, US
Founded2011
Size (employees)20 (est)
Websitebiopharmx.com
BioPharmX was founded in 2011 and is headquartered in Menlo Park, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

BioPharmX Office Locations

BioPharmX has an office in Menlo Park
Menlo Park, (HQ)
d 1505 Adams Dr
Show all (1)
Report incorrect company information

BioPharmX Financials and Metrics

BioPharmX Revenue

BioPharmX 's revenue was reported to be $73 k in FY, 2018
USD

Revenue (Q2, 2019)

24.0k

Gross profit (Q2, 2019)

11.0k

Gross profit margin (Q2, 2019), %

45.8%

EBIT (Q2, 2019)

(4.5m)

Market capitalization (4-Dec-2018)

30.1m

Closing stock price (4-Dec-2018)

0.2

Cash (31-Jul-2018)

6.6m
BioPharmX 's current market capitalization is $30.1 m.
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018

Revenue

64.0k100.0k73.0k

Cost of goods sold

237.0k516.0k250.0k

Gross profit

(173.0k)(416.0k)(177.0k)

Gross profit Margin, %

(270%)(416%)(242%)
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

5.0k20.0k33.0k19.0k33.0k19.0k17.0k18.0k18.0k24.0k

Cost of goods sold

10.0k19.0k20.0k17.0k28.0k11.0k9.0k8.0k7.0k13.0k

Gross profit

(5.0k)1.0k13.0k2.0k5.0k8.0k8.0k10.0k11.0k11.0k

Gross profit Margin, %

(100%)5%39%11%15%42%47%56%61%46%
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018

Cash

162.04.0m6.5m7.6m

Accounts Receivable

7.0k4.0k7.0k

Inventories

100.0k38.0k10.0k

Current Assets

39.0k4.4m6.8m8.0m
Quarterly
USDQ3, 2014Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

1.2m7.4m2.2m4.0m436.0k468.0k6.7m4.5m1.6m10.9m6.6m

Accounts Receivable

33.0k9.0k6.0k1.0k7.0k3.0k2.0k8.0k5.0k16.0k

Inventories

364.0k336.0k76.0k112.0k77.0k30.0k20.0k15.0k6.0k13.0k

Current Assets

1.5m8.2m2.8m4.4m1.0m1.3m7.0m5.0m2.2m11.3m7.3m
Annual
USDFY, 2013FY, 2016FY, 2017FY, 2018

Net Income

(52.3k)(15.6m)(18.4m)(16.6m)

Depreciation and Amortization

207.056.0k141.0k52.0k

Inventories

60.0k62.0k28.0k

Accounts Payable

446.0k625.0k774.0k(1.2m)
Quarterly
USDY, 2018

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

BioPharmX Online and Social Media Presence

Embed Graph
Report incorrect company information

BioPharmX News and Updates

BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain...

BioPharmX Receives Notice of Noncompliance from NYSE American

MENLO PARK, Calif., Sept. 28, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, received a notice on September 24, 2018 from the NYSE American LLC (the "NYSE American") that...

BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

MENLO PARK, Calif., Sept. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer. Anja Krammer...

BioPharmX Reports Second Quarter 2019 Financial Results

MENLO PARK, Calif., Aug. 30, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial results for the quarter ended July 31, 2018. "This quarter has been filled with...

BioPharmX Announces Results of Annual Shareholders Meeting

MENLO PARK, Calif., Aug. 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today held its 2018 Annual Meeting of Shareholders (the "Annual Meeting"), and announced that each of...
Report incorrect company information

BioPharmX Blogs

BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

Trial will evaluate 1% concentration of minocycline carried by company's patented HyantX™ delivery system

BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

Open-label feasibility study results identify BPX-04 topical minocycline gel, 1% as optimal dose for phase 2 trial

BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01

Waiver eliminates years of additional dermal carcinogenicity studies

BioPharmX Company Life and Culture

Report incorrect company information

BioPharmX Frequently Asked Questions

  • When was BioPharmX founded?

    BioPharmX was founded in 2011.

  • How many employees does BioPharmX have?

    BioPharmX has 20 employees.

  • What is BioPharmX revenue?

    Latest BioPharmX annual revenue is $73 k.

  • What is BioPharmX revenue per employee?

    Latest BioPharmX revenue per employee is $3.7 k.

  • Who are BioPharmX competitors?

    Competitors of BioPharmX include Repros Therapeutics, Clinipace Worldwide and TherapeuticsMD.

  • Where is BioPharmX headquarters?

    BioPharmX headquarters is located at d 1505 Adams Dr, Menlo Park.

  • Where are BioPharmX offices?

    BioPharmX has an office in Menlo Park.

  • How many offices does BioPharmX have?

    BioPharmX has 1 office.